The validity of atypical depression in DSM-IV. (Q41227986)

28 September 2017

1 reference

title

The validity of atypical depression in DSM-IV. (English)

1 reference

28 September 2017

Lam RW

1

1 reference

PubMed ID

8932961

28 September 2017

Stewart JN

series ordinal

2

1 reference

28 September 2017

1 November 1996

1 reference

28 September 2017

Comprehensive Psychiatry

1 reference

28 September 2017

37

1 reference

28 September 2017

6

1 reference

28 September 2017

375-383

1 reference

Effects of iproniazid in depressive syndromes.

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Establishment of Diagnostic Validity in Psychiatric Illness: Its Application to Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Drugs in the Treatment of Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Depressive Classification and Prediction of Response to Phenelzine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Nosology of atypical depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Symptoms of interpersonal sensitivity in depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Hysteroid dysphoria: an unsuccessful attempt to demonstrate its syndromal validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

The validity of major depression with atypical features based on a community study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Atypical depression: clinical aspects and noradrenergic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Hypersomnia and manic-depressive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Behavioural measurement and drug response characteristics of unipolar and bipolar depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Sleep EEG and DST findings in anergic bipolar depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Seasonal affective disorder--a British sample. Symptomatology in relation to mode of referral and diagnostic subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Light treatment of seasonal affective disorder in Switzerland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Seasonal Affective Disorder - A Canadian Sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Multi-center study of seasonal affective disorders in Japan. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Predictors of response to phototherapy in seasonal affective disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Atypical depressive symptoms possibly predict responsiveness to phototherapy in seasonal affective disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Morning light therapy for winter depression: predictors of response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

High intake of sweets late in the day predicts a rapid and persistent response to light therapy in winter depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Seasonality in atypical depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

The early course of atypical depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Prediction of tricyclic antidepressant response: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Predictors of drug response in depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Monoamine oxidase inhibitors. A review of antidepressant effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Antidepressant specificity in atypical depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Response to phenelzine and amitriptyline in subtypes of outpatient depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Forms of atypical depression and their response to antidepressant drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Predictors of response to monoamine oxidase inhibitors: Do they exist?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Tranylcypromine versus imipramine in anergic bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Moclobemide and fluoxetine in atypical depression: a double-blind trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Sleep of atypical depressives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

The tyramine challenge test as a marker for melancholia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

Cerebral laterality and depression: differences in perceptual asymmetry among diagnostic subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2896%2990020-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0010-440X(96)90020-6

1 reference

28 September 2017

1 reference

PubMed ID

8932961